Snapshot

The New Chemical Entity approved & marketed in other countries not approved in India. pathway has been developed by the of India.

This pathway can be used where new drugs approved & marketed in other countries but not approved in India..

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from Australia Canada EU-EMA Japan United Kingdom United States

Info not found.